Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia
- PMID: 30543595
Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia
Similar articles
-
Tisagenlecleucel (Kymriah) for ALL.Med Lett Drugs Ther. 2017 Oct 23;59(1532):177-178. Med Lett Drugs Ther. 2017. PMID: 29039821 No abstract available.
-
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6. Clin Cancer Res. 2018. PMID: 30190371 Free PMC article.
-
Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.Br J Haematol. 2024 Jul;205(1):373-377. doi: 10.1111/bjh.19524. Epub 2024 May 12. Br J Haematol. 2024. PMID: 38735758 No abstract available.
-
Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.Expert Rev Anticancer Ther. 2018 Oct;18(10):959-971. doi: 10.1080/14737140.2018.1512411. Expert Rev Anticancer Ther. 2018. PMID: 30111196 Free PMC article. Review.
-
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Immunotherapy. 2015;7(5):545-61. doi: 10.2217/imt.15.6. Immunotherapy. 2015. PMID: 26065479 Free PMC article. Review.
Cited by
-
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.Nat Commun. 2021 Dec 10;12(1):7200. doi: 10.1038/s41467-021-27312-6. Nat Commun. 2021. PMID: 34893603 Free PMC article.
-
Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy.Pediatr Blood Cancer. 2020 May;67(5):e28249. doi: 10.1002/pbc.28249. Epub 2020 Mar 11. Pediatr Blood Cancer. 2020. PMID: 32159278 Free PMC article. Review.
-
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.Paediatr Drugs. 2020 Feb;22(1):1-11. doi: 10.1007/s40272-019-00370-6. Paediatr Drugs. 2020. PMID: 31749131
-
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020. Haematologica. 2020. PMID: 31753925 Free PMC article.
-
Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.Blood Res. 2023 Apr 30;58(S1):S20-S28. doi: 10.5045/br.2023.2023026. Epub 2023 Mar 9. Blood Res. 2023. PMID: 36891576 Free PMC article. Review.